Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An efficacy and safety study of Tenofovir Versus Lamivudine in preventing Hepatitis B Virus reactivation in HBsAg-positive patients with advanced-stage diffuse large B cell (DLBC), non-Hodgkin lymphoma (NHL) or classic Hodgkin lymphoma

Trial Profile

An efficacy and safety study of Tenofovir Versus Lamivudine in preventing Hepatitis B Virus reactivation in HBsAg-positive patients with advanced-stage diffuse large B cell (DLBC), non-Hodgkin lymphoma (NHL) or classic Hodgkin lymphoma

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 25 Jul 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Lamivudine (Primary) ; Tenofovir dipivoxil fumarate (Primary)
  • Indications Hepatitis B
  • Focus Adverse reactions; Pharmacodynamics; Therapeutic Use
  • Most Recent Events

    • 25 Jul 2018 New trial record
    • 17 Jun 2018 Results presented at the 23rd Congress of the European Haematology Association
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top